Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim has signed a manufacturing agreement with Servier and its partner XOMA to produce gevokizumab at its facility in Biberach, Germany, for Servier's commercial use.
Subscribe to our email newsletter
As a part of the agreement, XOMA’s technology and process for the commercial manufacture of gevokizumab, XOMA’s novel interleukin 1-beta allosteric modulating antibody will be transferred to Boehringer.
After the completion of the transfer and the establishment of biological comparability, Boehringer will produce gevokizumab, which currently is in Phase 3 clinical development in patients with non-infectious uveitis.
XOMA chief executive officer John Varian said together with Servier, XOMA selected Boehringer Ingelheim because they are well recognized in manufacturing monoclonal antibodies at a commercial scale.
"Ultimately, we wanted a partner who could produce materials in both Europe and the U.S., and with Boehringer Ingelheim, we will have that capability," Varian added.
Under the agreement, Servier and XOMA retain all rights to the development and commercialization of gevokizumab. Financial terms of the agreement were not revealed.